GW 409890
Latest Information Update: 02 Aug 2023
At a glance
- Originator GlaxoSmithKline
- Class Obesity therapies
- Mechanism of Action Peroxisome proliferator-activated receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 22 May 2001 No-Development-Reported for Obesity in United Kingdom (Unknown route)
- 23 Jan 2001 Glaxo Wellcome has merged with SmithKline Beecham to form GlaxoSmithKline
- 28 Jan 1998 Preclinical development for Obesity in United Kingdom (Unknown route)